Incize SRL
3.0 FTEThe score of Incize shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +507 % Total assets +127 % Headcount (avg FTE) -70 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Incize's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 14 Aug 2026
- Year ended 31 Dec 2024filed on 26 Jun 2025
- Year ended 31 Dec 2023filed on 20 May 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 06 Sep 2022
Incize's financial analysis
- Solvency31.8%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Incize
Incize's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0548.752.952
- VAT number
- BE0548752952
- Peppol
- Registered · 0208:0548752952 · as of 29 Oct 2026
- Legal form
- SRL
- Incorporated
- 14 Mar 2014
- Registered office
- 1348 Ottignies-Louvain-la-Neuve
- Size
- Micro · 3.0 FTE
- Latest accounts
- 2025 · filed on 14 Aug 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Incize (SRL) has been based in Ottignies-Louvain-la-Neuve since 2014, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 5,125 € and equity of 877,146 €; its revenue is not published. With 3.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 31.8%, below the median of its sector (58.2%).
Companies similar to Incize
Companies in the same business, of comparable size and area, outside its group.
- Axis44 Research and experimental development on natural sciences and engineering Jodoigne · balance sheet €2.45m
- CTTec Research and experimental development on natural sciences and engineering Menen · balance sheet 259,750 €
- Medisearch International Research and experimental development on natural sciences and engineering Bree · balance sheet 58,762 €
- DR. Johan Vanden Broucke Research and experimental development on natural sciences and engineering Ypres · balance sheet €1.88m
- Oncoradiomics Research and experimental development on natural sciences and engineering Liège · balance sheet €4.31m
- Drs Pipeleers & Marichal Research and experimental development on natural sciences and engineering Roosdaal · balance sheet €2.05m
- Dokter Chielens Research and experimental development on natural sciences and engineering Poperinge · balance sheet €1.30m
- ProtonW.be Research and experimental development on natural sciences and engineering Charleroi · balance sheet €1.27m
Frequently asked questions about Incize
What is the revenue of Incize?
Incize files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Incize?
In Belgium, the VAT number is the company number prefixed with BE: BE0548752952 for Incize, if the company is VAT-registered. Its company number (CBE) is 0548.752.952.
Where is the registered office of Incize?
According to the CBE register, the registered office of Incize is in 1348 Ottignies-Louvain-la-Neuve.
What is the equity of Incize?
At the close of the 2025 financial year, the equity of Incize amounts to 877,146 €, a solvency of 31.8% of total assets.
How many people work at Incize?
3.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Incize?
The register lists 1 active mandates at Incize. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Incize
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →